Anergis appoints seasoned US vaccine and biotech executive to its Board of Directors
Anergis, a company focusing on proprietary allergy vaccines, announced the appointment of Dino Dina, MD, to its Board of Directors. During his tenure at Dynavax, he secured extensive financing through corporate alliances (UCB, Sanofi, AstraZeneca, GSK, Merck), private financings, an initial public offering (2004), and a series of public equity financings.
Dino Dina brings extensive expertise in the research and development of vaccines for allergy, cancer and infectious diseases as well as in building successful US biopharmaceutical companies. From 1998 to 2013, Dina served as Chief Executive Officer of Dynavax Technologies Corporation and has been a member of Dynavax´ Board of Directors since 1997.
Prior to joining Dynavax, Dr. Dina held a series of positions with increasing responsibility at Chiron Corporation, where he ultimately served as President of Chiron Vaccines. Under Dina’s direction, Chiron Vaccines received the first-ever approval of an adjuvanted influenza vaccine in Italy, successfully completed development of the first genetically engineered pertussis vaccine, and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus, and hepatitis B infections.
"We are delighted to welcome Dr. Dina as a board member of Anergis," said Jacques-François Martin, Chairman of Anergis´ Board of Directors. "With his outstanding track record he will surely play an essential role in further advancing Anergis´ business strategy."
"Dr. Dina also brings specific allergy vaccine experience from the Dynavax TOLAMBA program," added Vincent Charlon, Chief Executive Officer of Anergis. "As we are progressing with the development of our clinical pipeline, Dr. Dina´s advice will be of tremendous value to us."
“I am very impressed by the data assembled to date by Anergis on its COP vaccine pipeline and technology,” said Dino Dina. “In my view, the COP approach promises a real breakthrough in treating allergies. Therefore, I am convinced that the company can build highly attractive commercial opportunities for its vaccines.”
Anergis’ COP (Contiguous Overlapping Peptide) technology can be applied to a broad spectrum of allergy indications. At present, Anergis is developing AllerT for the treatment of birch pollen allergy, AllerR for ragweed pollen allergies and AllerDM for dust mite allergies.
Please login or sign up to comment.
Commenting guidelines